Stocks and Investing Stocks and Investing
Thu, September 7, 2017
Wed, September 6, 2017

Vamil Divan Maintained (TEVA) at Sell with Increased Target to $14 on, Sep 6th, 2017


Published on 2024-10-25 22:38:45 - WOPRAI, Vamil Divan
  Print publication without navigation


Vamil Divan of JMP Securities, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Sell with Increased Target from $13 to $14 on, Sep 6th, 2017.

Vamil has made no other calls on TEVA in the last 4 months.



There are 9 other peers that have a rating on TEVA. Out of the 9 peers that are also analyzing TEVA, 7 agree with Vamil's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Liav Abraham of "Citigroup" Downgraded from Strong Buy to Hold on, Wednesday, August 16th, 2017
  • Douglas Tsao of "Barclays" Maintained at Hold with Decreased Target to $23 on, Monday, August 7th, 2017
  • Tyler Van Buren of "Cowen & Co." Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Aaron Gal of "Bernstein" Downgraded from Buy to Hold on, Friday, August 4th, 2017
  • Derek Archila of "Oppenheimer" Downgraded from Buy to Hold on, Thursday, August 3rd, 2017
  • Irina Rivkind Koffler of "Mizuho" Upgraded from Sell to Hold on, Friday, June 16th, 2017
  • Louise Chen of "Cantor Fitzgerald" Initiated at Hold and Held Target at $31 on, Thursday, June 15th, 2017


These are the ratings of the 2 analyists that currently disagree with Vamil


  • David Risinger of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $16 on, Monday, August 7th, 2017
  • Randall Stanicky of "RBC Capital" Downgraded from Buy to Sell on, Friday, August 4th, 2017
Contributing Sources